UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

Under the Securities Exchange Act of 1934 (Amendment No. 1)

IMMATICS N.V. (Name of Issuer)

Ordinary shares, nominal value €0.01 per share (Title of Class of Securities)

N44445109 (CUSIP Number)

December 31, 2021 (Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- □ Rule 13d-1(b)
- □ Rule 13d-1(c)
- ⊠ Rule 13d-1(d)
- * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

13 G

Page 2 of 14 Pages

1.	Name of R	eporting P	ersons		
	diarini IIa	nn DioToc	ch holding GmbH & Co. KG		
2.			te Box if a Member of a Group (See Instructions)		
			• • •		
2		(b) □ ⁽¹⁾			
3.	SEC USE (JNLY			
4.	Citizenship	or Place o	of Organization		
	Germany				
		5.	Sole Voting Power		
N	1		0 ordinary shares		
	iber of <u>.</u> ares	6.	Shared Voting Power		
	ficially		(7, 200, 255, 1) (2)		
	ned by ach	7.	17,202,355 ordinary shares ⁽²⁾ Sole Dispositive Power		
Rep	orting				
-	rson /ith:	8.	0 ordinary shares Shared Dispositive Power		
		0.	Shared Dispositive Power		
			17,202,355 ordinary shares ⁽²⁾		
9.	Aggregate	Amount B	eneficially Owned by Each Reporting Person		
	17,202,355	ordinary s	shares ⁽²⁾		
10.			te Amount in Row (9) Excludes Certain Shares (See Instructions) \Box		
11.	. Percent of Class Represented by Amount in Row (9)				
		···· ·P·			
10	27.3% ⁽³⁾				
12.	Type of Re	porting Pe	erson (See Instructions)		
	00				

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.
- (3) This percentage is calculated based on 62,909,231 shares of the Issuer's ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

13 G

Page 3 of 14 Pages

Name of Rep	porting P	ersons	
DH-LT-Inve	estments	GmbH	
		e Box if a Member of a Group (See Instructions)	
(\mathbf{a}) \Box (\mathbf{a})	b) □ (1)		
Citizonchin	n Diaco c	+ Organization	
Cluzenship	or Place C	o organization	
Germany			
	5.	Sole Voting Power	
per of		0 ordinary shares	
ires	6.	Shared Voting Power	
		726,282 ordinary shares ⁽²⁾	
ch	7.	Sole Dispositive Power	
orting son		0 ordinary shares	
th:	8.	Shared Dispositive Power	
		726,282 ordinary shares ⁽²⁾	
Aggregate A	mount B	eneficially Owned by Each Reporting Person	
F OC 202 1		(2)	
	5	te Amount in Row (9) Excludes Certain Shares (See Instructions)	
	00 0		
Percent of C	lass Repr	esented by Amount in Row (9)	
1.2% ⁽³⁾			
	orting Pe	rson (See Instructions)	
	Check the A (a) [(I) SEC USE O Citizenship of Germany Deer of ires icially ed by ch rting son th: Aggregate A 726,282 ordi Check if the Percent of C 1.2% ⁽³⁾	(a) (b) (1) SEC USE ONLY Citizenship or Place of Germany 5. oer of res 6. icially ed by ch 7. ring son th: 8. 726,282 ordinary shar Check if the Aggregat Percent of Class Repr 1.2%(3) Type of Reporting Percent	

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.
- (3) This percentage is calculated based on 62,909,231 shares of the Issuer's ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

13 G

Page 4 of 14 Pages

1.	Name of R	eporting Po	ersons		
2	DH-Capita		& Co. KG re Box if a Member of a Group (See Instructions)		
2.	Спеск the .	Арргоргіа	e Box if a Member of a Group (See Instructions)		
	(a) 🗆	(b) 🗆 ⁽¹⁾			
3.	SEC USE				
4.	Citizonchin	or Diaco o	of Organization		
4.	Citizensiii		Ji Organization		
	Germany				
		5.	Sole Voting Power		
Num	ber of		0 ordinary shares		
	ares	6.	Shared Voting Power		
	ficially		(2)		
	ned by ach	7.	17,202,355 ordinary shares ⁽²⁾ Sole Dispositive Power		
	orting	7.	Sole Dispositive Power		
Pe	rson		0 ordinary shares		
W	'ith:	8.	Shared Dispositive Power		
			17,202,355 ordinary shares ⁽²⁾		
9.	Aggregate	Amount B	eneficially Owned by Each Reporting Person		
	17 202 255	ordinami	shares common shares ⁽²⁾		
10.			te Amount in Row (9) Excludes Certain Shares (See Instructions) \Box		
11.	11. Percent of Class		tt of Class Represented by Amount in Row (9)		
	27.3% ⁽³⁾				
12.		porting Pe	rson (See Instructions)		
	00				

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.
- (3) This percentage is calculated based on 62,909,231 shares of the Issuer's ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

13 G

Page 5 of 14 Pages

1.	Name of I	Reporting Pe	ersons		
	OV D				
2.			mbH & Co. KG e Box if a Member of a Group (See Instructions)		
2.	Check the	Арргорнас	e box if a Member of a Group (See instructions)		
	(a) 🗆	(b) 🗆 ⁽¹⁾			
3.	SEC USE	ONLY			
4.	Citizenshi	p or Place o	f Organization		
	Germany				
		5.	Sole Voting Power		
N	1		0 ordinary shares		
	nber of	6.	Shared Voting Power		
Bene	eficially				
	ned by		17,202,355 ordinary shares ⁽²⁾		
	lach orting	7.	Sole Dispositive Power		
Pe	erson		0 ordinary shares		
W	/ith:	8.	Shared Dispositive Power		
			17,202,355 ordinary shares ⁽²⁾		
9.	Aggregate	e Amount B	eneficially Owned by Each Reporting Person		
	17.202.35	5 ordinary s	hares ⁽²⁾		
10.					
11					
11.	Percent of	Percent of Class Represented by Amount in Row (9)			
	27.3% ⁽³⁾	27.3% ⁽³⁾			
12.	Type of R	eporting Pei	rson (See Instructions)		
	00				
L	1				

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.
- (3) This percentage is calculated based on 62,909,231 shares of the Issuer's ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

Page 6 of 14 Pages

1.	Name of R	eporting Pe	ersons	
	Dietmar H	lonn		
2.			e Box if a Member of a Group (See Instructions)	
	(a) 🗆	(b) □ ⁽¹⁾		
3.	SEC USE (
4.	Citizonchir	or Diaco o	f Organization	
4.	-			
	Germany		Cole Mething Decision	
		5.	Sole Voting Power	
Num	ber of		0 ordinary shares	
-	ares	6.	Shared Voting Power	
	ficially led by		17,202,355 ordinary shares ⁽²⁾	
Ea	ach	7.	Sole Dispositive Power	
	orting rson		0 ordinary shares	
W	ith:	8.	Shared Dispositive Power	
			17,202,355 ordinary shares ⁽²⁾	
9.	Aggregate	Amount B	eneficially Owned by Each Reporting Person	
	17.202.355	ordinary s	hares ⁽²⁾	
10.	17,202,355 ordinary shares ⁽²⁾ Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □			
11.	Percent of Class Represented by Amount in Row (9)			
11.	reicent of	Ciass Repr	esence by Amount in Now (5)	
	27.3% ⁽³⁾			
12.	Type of Re	porting Per	rson (See Instructions)	
	IN			

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.
- (3) This percentage is calculated based on 62,909,231 shares of the Issuer's ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

Page 7 of 14 Pages

1.	Name of Re	porting P	ersons		
	Oliver Hop	n			
2.			e Box if a Member of a Group (See Instructions)		
	(a) 🗆 (b) 🗆 ⁽¹⁾			
3.	SEC USE O				
4.	Citizenshin	or Dlace c	of Organization		
4.	_				
	Germany				
		5.	Sole Voting Power		
Num	ber of		0 ordinary shares		
Sh	ares	6.	Shared Voting Power		
	ficially ied by		17,202,355 ordinary shares ⁽²⁾		
Ea	ach	7.	Sole Dispositive Power		
	orting rson		0 ordinary shares		
W	ith:	8.	Shared Dispositive Power		
			17,202,355 ordinary shares ⁽²⁾		
9.	Aggregate A	mount B	eneficially Owned by Each Reporting Person		
	17,202,355	ordinary s	shares ⁽²⁾		
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)				
11.	Percent of Class Represented by Amount in Row (9)				
11.	Percent of C	lass kepi	esented by Amount in Row (9)		
	27.3% ⁽³⁾				
12.	Type of Rep	orting Pe	rson (See Instructions)		
	IN				

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.
- (3) This percentage is calculated based on 62,909,231 shares of the Issuer's ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

Page 8 of 14 Pages

1.	Name of Re	porting P	ersons		
2	Daniel Hop				
2.	Check the <i>P</i>	Appropriat	e Box if a Member of a Group (See Instructions)		
	(a) 🗌 (b) □ ⁽¹⁾			
3.	SEC USE C				
4.	Citizenshia	au Dlaas a	of Organization		
4.	Citizenship	or Place c	of Organization		
	Germany				
		5.	Sole Voting Power		
N	ber of		0 ordinary shares		
	ares	6.	Shared Voting Power		
Benef	ficially				
	ed by		17,202,355 ordinary shares ⁽²⁾		
	ach orting	7.	Sole Dispositive Power		
	rson		0 ordinary shares		
W	ith:	8.	Shared Dispositive Power		
			17,202,355 ordinary shares ⁽²⁾		
9.	Aggregate A	Amount B	eneficially Owned by Each Reporting Person		
			. (2)		
10.	17,202,355	U	te Amount in Row (9) Excludes Certain Shares (See Instructions)		
10.		Aggrega			
11.	11. Percent of Class Represented by Amount in Row (9)		esented by Amount in Row (9)		
	27.3% ⁽³⁾				
12.		orting Pe	rson (See Instructions)		
12,	Type of het	Joiting I C			
	IN				

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.
- (3) This percentage is calculated based on 62,909,231 shares of the Issuer's ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

13 G

Page 9 of 14 Pages

1.	Name of Repor	rting P	ersons	
	Drof Dr Erio	lrich y	von Bohlen und Halbach	
2.			e Box if a Member of a Group (See Instructions)	
		-		
		□ ⁽¹⁾		
3.	SEC USE ONI	_Y		
4.	Citizenship or 1	Place c	of Organization	
	Germany			
		5.	Sole Voting Power	
			0 ordinary shares	
-	ber of	6.	Shared Voting Power	
Bene	ficially			
	ned by ach	7.	17,202,355 ordinary shares ⁽²⁾ Sole Dispositive Power	
	orting	/.	Sole Dispositive Power	
-	rson		0 ordinary shares	
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	'ith:	8.	Shared Dispositive Power	
			17,202,355 ordinary shares ⁽²⁾	
9.	Aggregate Am	ount B	eneficially Owned by Each Reporting Person	
	17,202,355 ord	inary s	shares ⁽³⁾	
10.			te Amount in Row (9) Excludes Certain Shares (See Instructions) 🗆	
11.	Percent of Class Represented by Amount in Row (9)			
11.	reicent of Clas	s repi	esented by Amount in Kow (3)	
	27.3% ⁽⁵⁾			
12.	Type of Report	ing Pe	rson (See Instructions)	
	IN			

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.
- (3) This percentage is calculated based on 62,909,231 shares of the Issuer's ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

Page 10 of 14 Pages

1.	Name of R	Reporting Pe	ersons		
	Drof Dr (	[•] hristof U	attich .		
2.	Prof. Dr. Christof Hettich         Processor         Check the Appropriate Box if a Member of a Group (See Instructions)				
	(a) 🗆	(b) □ ⁽¹⁾			
3.	SEC USE	ONLY			
4.	Citizenshij	p or Place o	of Organization		
	Germany				
		5.	Sole Voting Power		
NT	ber of		0 ordinary shares		
	ares	6.	Shared Voting Power		
	ficially				
	ied by ach	7.	17,202,355 ordinary shares ⁽²⁾ Sole Dispositive Power		
Rep	orting				
-	rson ïth:		0 ordinary shares		
vv	1(1):	8.	Shared Dispositive Power		
			17,202,355 ordinary shares ⁽²⁾		
9.	Aggregate	Amount B	eneficially Owned by Each Reporting Person		
	17,202,355	5 ordinary s	hares		
10.					
11.	Percent of Class Represented by Amount in Row (9)				
11,	I ciccii oi	Сназэ терг			
		27.3 ⁽³⁾			
12.	Type of Re	eporting Per	rson (See Instructions)		
	IN				

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.
- (3) This percentage is calculated based on 62,909,231 shares of the Issuer's ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

Page 11 of 14 Pages

1.	Name of Re	eporting P	ersons		
	Dr Mathia	o Uothuw			
2.	Dr. Mathias Hothum         2.       Check the Appropriate Box if a Member of a Group (See Instructions)				
		(b) □ ⁽¹⁾			
3.	SEC USE C	ONLY			
4.	Citizenship	or Place o	of Organization		
	Germany				
		5.	Sole Voting Power		
			0 ordinary shares		
	ber of ares	6.	Shared Voting Power		
	ficially				
	ied by ach	7.	17,202,355 ordinary shares ⁽²⁾ Sole Dispositive Power		
	orting	7.	Sole Dispositive Power		
	rson		0 ordinary shares		
W	ïth:	8.	Shared Dispositive Power		
			17,202,355 ordinary shares ⁽²⁾		
9.	Aggregate A	Amount B	eneficially Owned by Each Reporting Person		
	17,202,355	ordinary s	shares		
10.					
11	Percent of Class Represented by Amount in Row (9)				
11.	Percent of C	Liass Repr	esented by Amount in Row (9)		
	27.3 ⁽³⁾				
12.	Type of Rep	porting Pe	rson (See Instructions)		
	IN				

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.
- (3) This percentage is calculated based on 62,909,231 shares of the Issuer's ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

13 G

Page 12 of 14 Pages

Introductory Note: This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments, GmbH ("DH-LT-Investments"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH & Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons") in respect of ordinary shares of Immatics N.V.

#### Item 1(a) Name of Issuer:

Immatics N.V.

#### Item 1(b) Address of Issuer's principal executive offices:

Paul-Ehrlich-Straße 15 72076 Tübingen, Germany

#### Items 2(a) Name of Reporting Persons filing:

dievini Hopp BioTech holding GmbH & Co. KG ("dievini") DH-LT-Investments GmbH ("DH-LT-Investments") DH-Capital GmbH & Co. KG ("DH-Capital") OH Beteiligungen GmbH & Co. KG ("OH Beteiligungen") Dietmar Hopp Oliver Hopp Daniel Hopp Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen") Prof. Dr. Christof Hettich ("Dr. Hettich") Dr. Mathias Hothum ("Dr. Hothum")

#### Item 2(b) Address or principal business office or, if none, residence:

The address of the principal business office of dievini, DH-LT Investments, Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum is c/o dievini Hopp BioTech holding GmbH & Co. KG, Johann-Jakob-Astor Straße 57, 69190 Walldorf, Germany.

The address of the principal business office of DH-Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG is Heidelberger Straße 43, 69168 Wiesloch, Germany.

The address of the principal business office of Oliver Hopp is Johann-Jakob-Astor-Straße 59, 69190 Walldorf, Germany.

The address of the principal business office of Daniel Hopp is Johann-Jakob-Astor-Straße 57, 69190 Walldorf, Germany.

### Item 2(c) Citizenship:

Name	Citizenship or Place of Organization
Dievini	Germany
DH-Capital	Germany
OH Beteiligungen	Germany
Dietmar Hopp	Germany
Oliver Hopp	Germany
Daniel Hopp	Germany
Dr. von Bohlen	Germany
Dr. Hettich	Germany
Dr. Hothum	Germany
DH-LT Investments	Germany

13 G

Item 2(d)	Title of class of securities:
	Ordinary shares, nominal value €0.01 per share.
Item 2(e)	CUSIP No.:
	N44445109
Item 3	If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:
	Not applicable.
Item 4	Ownership
	The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
Item 5	Ownership of Five Percent or Less of a Class
	If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: $\Box$
Item 6	Ownership of More than Five Percent on Behalf of Another Person
	Not applicable.
Item 7	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
	Not applicable.
Item 8	Identification and Classification of Members of the Group
	Not applicable.
Item 9	Notice of Dissolution of Group
	Not applicable.
Item 10	Certifications
	Not applicable.

13 G

Page 14 of 14 Pages

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2022

#### DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG

- By: dievini Verwaltungs GmbH its General Partner
- By: /s/ Dr. Marc Hauser Name: Dr. Marc Hauser Title: Attorney-in-fact

## DH-CAPITAL GMBH & CO. KG

- By: DH Verwaltungs GmbH its General Partner
- By: /s/ Dr. Marc Hauser Name: Dr. Marc Hauser Title: Attorney-in-fact

# **OH BETEILIGUNGEN GMBH & CO. KG**

- By: OH Verwaltungs GmbH its General Partner
- By: /s/ Dr. Marc Hauser Name: Dr. Marc Hauser Title: Attorney-in-fact

### /s/ Dr. Marc Hauser as attorney-in-fact **DIETMAR HOPP**

/s/ Dr. Marc Hauser as attorney-in-fact
OLIVER HOPP

/s/ Dr. Marc Hauser as attorney-in-fact **DANIEL HOPP** 

/s/ Dr. Marc Hauser as attorney-in-fact FRIEDRICH VON BOHLEN UND HALBACH

/s/ Dr. Marc Hauser as attorney-in-fact CHRISTOF HETTICH

/s/ Dr. Marc Hauser as attorney-in-fact MATHIAS HOTHUM

# DH-LT INVESTMENTS GMBH

By: /s/ Dr. Marc Hauser Name: Dr. Marc Hauser

Title: Attorney-in-fact

Exhibit(s):

1 – <u>Power of Attorney</u>

2 – Joint Filing Statement

### POWER OF ATTORNEY

**KNOW ALL BY THESE PRESENTS** that each of the undersigned hereby constitutes and appoints Dr. Marc Hauser, Dr. Christina Eschenfelder and Dr. Moritz Weber of RITTERSHAUS Rechtsanwälte Partnerschaftsgesellschaft mbB, Harrlachweg 4, 68163 Mannheim, signing individually, the undersigned's true and lawful attorneys-in-fact and agents with respect to the undersigned's holdings of and transactions in securities issued by AC Immune, CureVac N.V., and immatics M.V. (each, a "<u>Company</u>") to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "<u>SEC</u>") filings pursuant to Section 13 (Schedule 13D and Schedule 13G), as applicable (including any amendments, exhibits, joint filing agreements or other documents related thereto or in connection therewith) with respect to the securities of the Company in accordance with Section 13 of Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>") and any and all rules and regulations thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Schedule 13D and Schedule 13G, as applicable (including any amendments, exhibits, joint filing agreements or other documents related thereto or in connection therewith) and file the same with the SEC and any stock exchange, self-regulatory association or any other authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney in fact, or such attorney in fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Section 13 of the Exchange Act and the rules and regulations thereunder.

This Power of Attorney shall remain in full force and effect until the earlier of (i) the undersigned is no longer required to file such forms with respect to the undersigned's holdings of and transactions in securities issued by the Company or (ii) or until such time as the person or persons to whom power of attorney has been hereby granted cease(s) to perform the function in connection with which he/she was appointed attorney-in-fact or to be an employee of RITTERSHAUS Rechtsanwälte Partnerschaftsgesellschaft mbB or one of its affiliates, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in fact.

### [Signatures on Following Page]

IN WITNESS WHEREOF, each of the undersigned has caused this Power of Attorney to be executed as of this 21st day of August, 2020.

# DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG

- By: dievini Verwaltungs GmbH its General Partner
- By: /s/ Dr. Marc Hauser* Name: Dietmar Hopp Title: Managing Director
- By: Dr. Marc Hauser* Name: Mathias Hothum Title: Managing Director

# DH-CAPITAL GMBH & CO. KG

- By: BW Verwaltungs GmbH its General Partner
- By: /s/ Dr. Marc Hauser* Name: Dietmar Hopp Title: Managing Director

# **OH BETEILIGUNGEN GMBH & CO. KG**

- By: OH Verwaltungs GmbH its General Partner
- By: Dr. Marc Hauser* Name: Oliver Hopp Title: Managing Director

The manging Director

# **DH-LT-INVESTMENTS GMBH**

By: /s/ Dr. Marc Hauser* Name: Dr. Marc Hauser Title: Authorized Attorney-in-Fact

/s/ Dr. Marc Hauser*

DIETMAR HOPP

/s/ Dr. Marc Hauser* OLIVER HOPP

/s/ Dr. Marc Hauser* DANIEL HOPP

/s/ Dr. Marc Hauser* CHRISTOF HETTICH

/s/Dr. Marc Hauser* FRIEDRICH VON BOHLEN UND HALBACH

/s/ Dr. Marc Hauser* MATHIAS HOTHUM

* Pursuant to separate power of attorney to be filed by amendment

### JOINT FILING STATEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares of Immatics N.V. and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.

The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein or therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Each party to this Joint Filing Agreement agrees that this Joint Filing Agreement may be signed in counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, each of the undersigned has caused this Joint Filing Agreement to be executed as of this 7th day of February, 2022.

#### DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG

- By: dievini Verwaltungs GmbH its General Partner
- By: /s/ Dr. Marc Hauser
  - Name: Dr. Marc Hauser Title: Attorney-in-fact

#### DH-CAPITAL GMBH & CO. KG

- By: BW Verwaltungs GmbH its General Partner
- By: /s/ Dr. Marc Hauser Name: Dr. Marc Hauser Title: Attorney-in-fact

# **OH BETEILIGUNGEN GMBH & CO. KG**

- By: OH Verwaltungs GmbH its General Partner
- By: /s/ Dr. Marc Hauser Name: Dr. Marc Hauser Title: Attorney-in-fact

/s/ Dr. Marc Hauser as attorney-in-fact DIETMAR HOPP

/s/ Dr. Marc Hauser as attorney-in-fact OLIVER HOPP

/s/ Dr. Marc Hauser as attorney-in-fact
DANIEL HOPP

/s/ Dr. Marc Hauser as attorney-in-fact FRIEDRICH VON BOHLEN UND HALBACH

/s/ Dr. Marc Hauser as attorney-in-fact CHRISTOF HETTICH

/s/ Dr. Marc Hauser as attorney-in-fact MATHIAS HOTHUM

#### **DH-LT INVESTMENTS GMBH**

By: /s/ Dr. Marc Hauser, as attorney-in fact Name: Dr. Marc Hauser Title: Attorney-in-Fact